CVS HEALTH (AND SUBSIDIARIES) for CVS HEALTH (AND SUBSIDIARIES)
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to corporate tax reform and taxes included in the Affordable Care Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| TEGAN GELFAND | — |
| ASHLI PALMER New | Policy Director, Assistant Democratic Leader James Clyburn (D-SC) |
| SHANNON PENBERTHY | — |
| MELISSA SCHULMAN | — |
Communications/Broadcasting/Radio/TV COM
Issues related to the Telephone Consumer Protection Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TEGAN GELFAND | — |
Health Issues HCR
Issues related to implementation and changes to the Affordable Care Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| ASHLI PALMER New | Policy Director, Assistant Democratic Leader James Clyburn (D-SC) |
| SHANNON PENBERTHY | — |
| MELISSA SCHULMAN | — |
Medicare/Medicaid MMM
Issues related to Medicare Part D and Medicare payment for home infusion. S.637, The Creating Transparency to Have Drug Rebates Unlocked Act of 2017 S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Drug Spending Act of 2017 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017 H.R. 3528, The Every Prescription Conveyed Safely Act of 2017 S. 1738/H.R. 3163, The Medicare Home Infusion Therapy Act of 2017 H.R. 3178, The Medicare Part B Improvement Act of 2017 H.R. 3823, The Disaster Tax Relief and Airport and Airway Extension Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| ASHLI PALMER New | Policy Director, Assistant Democratic Leader James Clyburn (D-SC) |
| SHANNON PENBERTHY | — |
| MELISSA SCHULMAN | — |
Labor Issues/Antitrust/Workplace LBR
Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS. S. 214, The Preserve Access to Affordable Generics Act of 2017 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| ASHLI PALMER New | Policy Director, Assistant Democratic Leader James Clyburn (D-SC) |
| SHANNON PENBERTHY | — |
| MELISSA SCHULMAN | — |
Pharmacy PHA
Issues related to medication adherence, generic drug approvals, biologic exclusivity periods, and drug price transparency. H.R.1316, The Prescription Drug Price Transparency Act of 2017 S.771/H.R. 1776, The Improving Access To Affordable Prescription Drugs Act of 2017 H.R.749, The Lower Drug Costs Through Competition Act of 2017 S. 297, The Increasing Competition in Pharmaceuticals Act of 2017 S. 778/H.R. 1854, The Prescription Drug Monitoring Act of 2017 H.R. 3528, The Every Prescription Conveyed Safely Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH BROOKS | — |
| ASHLI PALMER New | Policy Director, Assistant Democratic Leader James Clyburn (D-SC) |
| SHANNON PENBERTHY | — |
| MELISSA SCHULMAN | — |
Veterans VET
Issues related to veterans access to healthcare and VA CHOICE Act reauthorization. S. 1526, The Veterans Access to Community Care Act of 2017
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHANNON PENBERTHY | — |
| MELISSA SCHULMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.